ROBERT HARRY REID
Medical Practice in Charnita, PA
License number
Pennsylvania MD055539L
Category
Medicine
Type
Medical Physician and Surgeon
Address
Address
Charnita, PA 17320
Personal information
See more information about ROBERT HARRY REID at radaris.comName
Address
Phone
50 Central Ave, Morrisville, PA 19067
44 Glenview Dr, Glenmoore, PA 19343
48 Lakeside Trl, Fairfield, PA 17320
4817 Gardenville Rd, Pittsburgh, PA 15236
119 Oak Hill Dr, Middletown, PA 17057
Professional information
Dr. Robert H Reid, Kensington MD - MD (Doctor of Medicine)
Specialties:
Internal Medicine, Allergy & Immunology
Address:
10807 Mccomas Ct, Kensington 20895
C.V.
48 Lakeside Trl SUITE C, Fairfield 17320
(717) 642-6213 (Phone)
C.V.
48 Lakeside Trl SUITE C, Fairfield 17320
(717) 642-6213 (Phone)
Certifications:
Allergy & Immunology, 1979, Internal Medicine, 1972
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Washington
Graduated: 1966
University of Washington
Graduated: 1966
Model For Testing Immunogenicity Of Peptides
US Patent:
6939546, Sep 6, 2005
Filed:
Jan 26, 1998
Appl. No.:
09/013077
Inventors:
Jeffrey Nauss - San Diego CA, US
Robert Reid - Fairfield PA, US
Marcia Kay Wolf - Silver Spring MD, US
Robert Reid - Fairfield PA, US
Marcia Kay Wolf - Silver Spring MD, US
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K039/00, G01N033/543
US Classification:
4241841, 4241851, 514 13, 514 14
Abstract:
Assay methods for determining whether a peptide is likely to be immunogenic are based on a computer modeling of binding to a Class II MHC DR1 receptor. This is confirmed by competitive inhibition binding assays. The peptides are useful for eliciting an immune response for vaccination or the production of antibodies or T-cells.
Model For Testing Immunogenicity Of Peptides
US Patent:
2005007, Apr 7, 2005
Filed:
Dec 17, 2003
Appl. No.:
10/738034
Inventors:
Jeffrey Nauss - San Diego CA, US
Robert Reid - Fairfield PA, US
Marcia Wolf - Sliver Spring MD, US
Scheherazade Sadegh-Nasseri - Baltimore MD, US
Robert Reid - Fairfield PA, US
Marcia Wolf - Sliver Spring MD, US
Scheherazade Sadegh-Nasseri - Baltimore MD, US
International Classification:
G01N033/53, G06F019/00, G01N033/48, G01N033/50
US Classification:
435007100, 702019000
Abstract:
Assay methods for determining whether a peptide is likely to be immunogenic are based on a computer modeling of binding to a Class II MHC DR1 receptor. This is confirmed by competitive inhibition binding assays. The peptides are useful for eliciting an immune response for vaccination or the production of antibodies or T-cells.
“Burst-Free” Sustained Release Poly-(Lactide/Glycolide) Microspheres
US Patent:
7033608, Apr 25, 2006
Filed:
Jun 22, 1999
Appl. No.:
09/337945
Inventors:
John E. Van Hamont - Fort Meade MD, US
Phil Friden - Bedford MA, US
Robert H. Reid - Fairfield PA, US
F. Donald Roberts - Dover MA, US
Charles E. McQueen - Olney MD, US
Jean A. Setterstrom - Silver Spring MD, US
Phil Friden - Bedford MA, US
Robert H. Reid - Fairfield PA, US
F. Donald Roberts - Dover MA, US
Charles E. McQueen - Olney MD, US
Jean A. Setterstrom - Silver Spring MD, US
Assignee:
The United States of America as represented by the Secretary of the Army - Washington DC
International Classification:
A61K 9/14, A61K 9/16, A61K 9/50
US Classification:
424490, 424489, 424491, 424493, 424496, 424501
Abstract:
Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1–100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer as a blend of uncapped (free carboxyl end group) and end-capped forms ranging in ratios from 100/0 to 1/99.